Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

10815	Companies
234323	Keywords
163107	Articles
125296	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 10/06/2025 at 11:00, 10 months 3 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 10 months 14 days ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
BRIEF

published on 09/26/2025 at 08:05, 10 months 14 days ago

Pentixapharm fait progresser PentixaTher dans l'essai sur la LAM

Essai Clinique Produits Radiopharmaceutiques Ciblage CXCR4 Leucémie Myéloïde Aiguë PentixaTher
PRESS RELEASE

published on 09/26/2025 at 08:00, 10 months 14 days ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 1 year 2 months ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 1 year 2 months ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 1 year 2 months ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 1 year 3 months ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
BRIEF

published on 04/25/2025 at 15:44, 1 year 3 months ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
PRESS RELEASE

published on 04/25/2025 at 15:39, 1 year 3 months ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 08/10/2026 at 08:00, 1 hour 20 minutes ago

Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 1 hour 20 minutes ago

Results of AGM and Management Update Presentation
Published on 08/08/2026 at 00:00, 2 days 9 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 2 days 10 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 10 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 09:00, 19 minutes ago

Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 19 minutes ago

Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 19 minutes ago

Official List Notice
Published on 08/10/2026 at 09:00, 20 minutes ago

Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
Published on 08/10/2026 at 08:30, 49 minutes ago

Suspension - Ashington Innovation PLC

Les Echos

Published on 08/10/2026 at 07:00, 2 hours 20 minutes ago

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 2 hours 20 minutes ago

Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
Published on 08/07/2026 at 18:54, 2 days 14 hours ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 14 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 14 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026

View all LES ECHOS COMFI WIRE